Latest Governance And Leadership News

PYC Therapeutics strengthened its financial footing with a $600 million capital raise and made notable clinical progress across four RNA therapeutic programs targeting genetic diseases.

Alterity Therapeutics posted a 285% jump in revenue to A$1.72 million but also a 93% rise in net loss to A$23.4 million for FY2026. The company secured FDA alignment on a single pivotal Phase 3 trial for ATH434 in Multiple System Atrophy, setting the stage for trial start by year-end.

Paradigm Biopharmaceuticals has surpassed its Phase 3 enrolment target for Zilosul®, secured over A$21 million in capital, and pivots towards clinical evidence generation with major data readouts expected.

HITIQ Limited posted a 21% drop in revenue to $1.59 million and reduced its net loss by 15% to $6.1 million for FY26, advancing commercialisation of its concussion management platform PROTEQT™ despite ongoing funding pressures and regulatory hurdles.

SPC Global reported a 27% rise in normalised EBITDA for FY26 to $38.5 million, supported by a $100 million equity raise that halved net leverage. The company’s strategic pivot to higher-margin branded products and operational efficiencies set the stage for targeted double-digit revenue and EBITDA growth in FY27.

Dubber Corporation Limited (ASX:DUB) posted a 17% revenue drop in FY26 to $35.1 million, mainly due to a major contract loss in Europe, but narrowed its net loss by 78% excluding impairments and achieved cash flow breakeven in H2.

Rhythm Biosciences marked its transition to commercialisation with first sales of ColoSTAT® and geneType™ tests, despite a 55% increase in loss to $5.93 million. The company expanded market access and secured manufacturing agreements, while NHS England began evaluating ColoSTAT® for bowel cancer screening.

Actinogen Medical reported a $15.38 million loss for FY2026 while progressing its lead Alzheimer's drug Xanamem toward pivotal trial results expected this November. The company secured regulatory alignment and strengthened its cash position to fund operations through mid-2027.

SenSen Networks reported a 16.7% rise in annualised recurring revenue to $11.7 million and a 23.6% EBITDA increase to $2.0 million in FY26, while expanding its SenDISA platform into environmental enforcement with EPA Victoria.

Clarity Pharmaceuticals reported a 67% increase in net loss to $107.2 million for FY26, driven by higher R&D spending, while advancing multiple Phase III trials and expanding manufacturing capacity ahead of commercialisation.

Hubify Limited posted an 89% jump in FY26 EBITDA to $0.66 million despite a 5% revenue dip, driven by a strategic shift to higher-margin managed technology and advisory services and a robust cash position of $3.79 million.

Redox Limited posted a strong FY26 with record revenue of $1.33 billion, a 19.2% jump in statutory net profit, and a 4% dividend increase, while announcing a board leadership transition.